Covered recipient · General Payments record
TIMOTHY PAUL KAO
Allopathic & Osteopathic Physicians Ophthalmology
General Payments · PY2019–2024
$2,103.81
- Reported across 74 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $656.88 | 18 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Alcon Laboratories Inc | $206.99 | 3 |
| Tarsus Pharmaceuticals, Inc. | $191.80 | 7 |
| Amgen Inc. | $168.77 | 4 |
| ABBVIE INC. | $69.80 | 3 |
| Thea Pharma Inc. | $19.52 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (18)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| ABBVIE INC. | $19.09 | 05/09/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1104029531 | CMS |
| ABBVIE INC. | $26.52 | 10/17/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1104029533 | CMS |
| ABBVIE INC. | $24.19 | 12/17/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1104029535 | CMS |
| Alcon Vision LLC | $21.30 | 04/15/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1110641545 | CMS |
| Alcon Vision LLC | $58.04 | 09/14/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1110641547 | CMS |
| Alcon Vision LLC | $127.65 | 10/24/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1110641549 | CMS |
| Amgen Inc. | $21.02 | 01/10/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1115786842 | CMS |
| Amgen Inc. | $22.31 | 04/23/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1115786852 | CMS |
| Amgen Inc. | $100.98 | 05/21/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1115786860 | CMS |
| Amgen Inc. | $24.46 | 08/19/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1115786869 | CMS |
| Tarsus Pharmaceuticals, Inc. | $31.09 | 02/06/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1139106669 | CMS |
| Tarsus Pharmaceuticals, Inc. | $30.62 | 02/28/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1139106671 | CMS |
| Tarsus Pharmaceuticals, Inc. | $38.76 | 06/18/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1139106673 | CMS |
| Tarsus Pharmaceuticals, Inc. | $10.90 | 08/02/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1139106675 | CMS |
| Tarsus Pharmaceuticals, Inc. | $34.83 | 08/06/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1139106677 | CMS |
| Tarsus Pharmaceuticals, Inc. | $19.49 | 09/12/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1139106679 | CMS |
| Tarsus Pharmaceuticals, Inc. | $26.11 | 09/17/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1139106681 | CMS |
| Thea Pharma Inc. | $19.52 | 01/26/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1074541933 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.